NICE has implemented new measures to evaluate the cost-effectiveness of medicines, following a policy change that aims to give patients improved access to treatments.

NICE is unable to make a recommendation on subcutaneous spesolimab (Spevigo) 1-ml formulation for preventing generalised pustular psoriasis flares in people 12 years and over. This is because the ...

Learn how the MHRA and NICE are getting medicines to patients 3 to 6 months sooner by delivering same time decisions on ...

Surgical insertion of a catheter-based left ventricular microaxial flow pump for cardiogenic shock HTG774 25 March 2026 25 March 2026 Percutaneous insertion of a catheter-based left ventricular ...

Evidence-based recommendations on dupilumab (Dupixent) for add-on maintenance treatment of uncontrolled chronic obstructive pulmonary disease (COPD) with raised blood eosinophils in adults ...

NICE is unable to make a recommendation on luspatercept (Reblozyl) for treating anaemia caused by myelodysplastic syndromes because BMS did not provide an evidence submission.

People who have had a heart attack, stroke, or serious circulation problem in their legs, and who also carry excess weight, can now be offered a weekly injection to help protect them from a further ...

There is a commercial access agreement for osimertinib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

This guidance has been updated and replaced by NICE technology appraisal guidance on pembrolizumab with pemetrexed and platinum chemotherapy for untreated ...

Evidence-based recommendations on dabrafenib (Tafinlar) plus trametinib (Mekinist) for BRAF V600 mutation-positive advanced non-small-cell lung cancer in adults. There is a commercial access agreement ...

This guideline covers the diagnosis, assessment and non-surgical management of osteoarthritis. It aims to improve management of osteoarthritis and the quality of life for people with osteoarthritis.

Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy Technology appraisal guidance TA673 Published: 17 ...